Drug
Octreotide
Octreotide: highest development phase Phase 3, developed by Endo, Sandoz. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Endo, Sandoz
Trials
| Drug | Phase | Indication |
|---|---|---|
| Octreotide NCT01295060 | Phase 3 | Acromegaly |
| Octreotide NCT00002252 | Not Applicable | Diarrhea |
| Octreotide NCT00002253 | Not Applicable | Diarrhea |
Latest
No recent events.
Follow Octreotide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.